Sangamo Therapeutics, Inc.SGMONASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank67
3Y CAGR-22.1%
5Y CAGR+16.2%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-22.1%/yr
vs +16.8%/yr prior
5Y CAGR
+16.2%/yr
Recent deceleration
Acceleration
-38.9pp
Decelerating
Percentile
P67
Within normal range
vs 5Y Ago
2.1x
Strong expansion
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $141.90M | -12.3% |
| 2024 | $161.77M | -64.1% |
| 2023 | $450.24M | +49.8% |
| 2022 | $300.47M | +2.2% |
| 2021 | $294.04M | +338.2% |
| 2020 | $67.10M | +8.8% |
| 2019 | $61.69M | -61.8% |
| 2018 | $161.60M | +73.9% |
| 2017 | $92.93M | +1.1% |
| 2016 | $91.95M | - |